Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

daclizumab

A recombinant monoclonal antibody interleukin-2 receptor antagonist. Daclizumab binds specifically to the alpha subunit of the human interleukin-2 (IL-2) receptor expressed on the surface of activated lymphocytes in vivo, thereby inhibiting IL-2 binding and IL-2-mediated lymphocyte activation, a critical cellular immune response pathway.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-Tac
Anti-Tac Humanized Monoclonal Antibody
anti-Tac monoclonal antibody
Dacliximab
US brand name:Zenapax
Abbreviation:MOAB anti-Tac
IND number:2091
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search